The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice
- 235 Downloads
Toxoplasmosis, a zoonotic parasitic disease, is a huge challenge for which there is no effective vaccine up till now. In this study, chitosan nanospheres encapsulated with Toxoplasma lysate vaccine was evaluated for its ability to protect mice against both acute and chronic toxoplasmosis models of infection. Results showed that chitosan nanospheres were equally effective to Freund’s incomplete adjuvant (FIA) in enhancing the efficacy of Toxoplasma lysate vaccine. The effectiveness was demonstrated by the delayed death of vaccinated mice following challenge either with virulent RH or avirulent Me49 strains, the significant decrease in parasite density in different organs, significant increase in the humoral and cellular immune response (IgG and IFN γ) with a marked reduction of pathological changes in the different organs. However chitosan nanospheres were superior to FIA due to their cost effective preparation and much less necrotic changes induced in the studied organs. The success of chitosan polymer as an alternative to commonly used adjuvants paves the way for the use of other newly developed polymers to be used in the field of vaccine development.
KeywordsCrude Toxoplasma lysate vaccine Virulent RH Toxoplasma strain Avirulent Me49 Toxoplasma strain Encapsulated chitosan nanospheres
We are grateful to Professor Ashraf Brakat, Department of Epidemiology and Zoonotic Diseases, National Research Center, Doki, Giza, Egypt for providing the avirulent Me49 Toxoplasma strain. Special thanks to Professor Rafaat Shaban, Epidemiology and Zoonotic Diseases, National Research Center, Doki and Dr. Mona Mohamed Tolba, Lecturer in Medical Research Institute for their assistance in ELISA technique. The technical support of Mrs. Neamat Ahmed Hassan is greatly appreciated.
Conflict of interests
We declare that the authors have no conflict of interest.
- Cambridge CD, Singh SR, Waffo AB, Fairley SJ, Dennis VA (2013) Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles. Int J Nanomed 8:1759–1771Google Scholar
- Chan YH (2003) Biostatistics 102: quantitative data—parametric & non-parametric tests. Singap Med J 44(8):391–396Google Scholar
- Cong H, Zhang M, Xin Q, Wang Z, Li Y, Zhao Q et al (2013) DNA vaccine encoding SAG1/SAG3 with A2/B subunit of cholera toxin as a genetic adjuvant protects BALB/c mice against Toxoplasma gondii. Parasites Vectors 6:63Google Scholar
- Danesh-Bahreinni MA, Shokri J, Samiel A, Kamali-Sarvestani E, Barzegar-Jalali M, Mohmmadi-Samani S (2011) Nanovaccine for leishmaniasis; preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/C mice. Int J Nanomed 6:835–842Google Scholar
- Drury RAB, Wallington EA (1980) Carleton’s Histological technique, 5th edn. Oxford University Press, OxfordGoogle Scholar
- El-Temsahy M, El-Kerdany ED, Abou-Shamaa AM (2002) Study of the role of antioxidants in experimental toxoplasmosis. J Med Res Inst 23:59–69Google Scholar
- Hermes G, Ajika JW, Kelly KA, Mui E, Roberts F, Kasza K et al (2008) Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neural injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflamm 5:48CrossRefGoogle Scholar
- Khan IA, Casciotti L (1999) IL-15 prolongs the duration of CD+8 T cell mediated immunity in mice infected with a vaccine strain of Toxoplasma gondii. J Immunol 16:34503–34509Google Scholar
- Kirkpatrick LA, Feeney BC (2013) A simple guide to IBM SPSS statistics for version 20.0, student ed. Wadsworth, Cengage Learning, Belmont, California, p 115Google Scholar
- Leslie E, Geoffrey J, James M (1991) Statistical analysis. In: Interpretation and uses of medical statistics, 4th edn. Oxford Scientific Publications, Oxford, pp 411–416Google Scholar
- Mady RFM (2005) Efficacy of killed vaccine against experimental toxoplasmosis. MS Thesis, Faculty of Medicine, Alexandria University, AlexandriaGoogle Scholar
- Shams El-Din SA (2013) Evaluation of vaccination with Toxoplasma gondii trophozoite lysate and influenza virus vaccine against experimental murine toxoplasmosis. Acta Parasitol Glob 4(3):110–120Google Scholar
- Tafaghodi M, Tabassi AS, Amiri N (2008) PLGA Nanospheres loaded with autoclaved Leishmania major (ALM) and CPG-ODN: preparation and in vitro characterization. Iran J Basic Med Sci 11(2):112–119Google Scholar
- Tiyaboonchai W (2003) Chitosan nanoparticles: a promising system for drug delivery. Naresuan Univ J 11(3):51–66Google Scholar
- Turner HJ (1983) Detection of soluble antigens of Toxoplasma gondii four-layer modification of an enzyme immunoassay. J Clin Microbiol 17(5):768–773Google Scholar
- Yap SG, Kersten TS, Ferguson DJ, Howe D, Susuki Y, Sher A (1998) Partially protective vaccination permits the development of latency in a normally virulent strain of Toxoplasma gondii. Infect Immunol 66(9):4382–4388Google Scholar